Evaluation of bone depth, cortical bone, and mucosa thickness of palatal posterior supra-alveolar insertion site for miniscrew placement

alexandrossfakianakis shared this article with you from Inoreader Evaluation of bone depth, cortical bone, and mucosa thickness of palatal posterior supra-alveolar insertion site for miniscrew placement via Progress in Orthodontics - Latest Articles The use of palatal miniscrew offers the possibility to improve the effectiveness of orthodontic expansion devices. Palatal expanders supported by miniscrew can be applied with different clinical protocols. Som... View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

The microbiome of cryospheric ecosystems

alexandrossfakianakis shared this article with you from Inoreader The microbiome of cryospheric ecosystems via Earth and environmental sciences : nature.com subject feeds View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Hippocampal avoidance prophylactic cranial irradiation (HA-PCI) for small cell lung cancer reduces hippocampal atrophy compared to conventional PCI

alexandrossfakianakis shared this article with you from Inoreader Hippocampal avoidance prophylactic cranial irradiation (HA-PCI) for small cell lung cancer reduces hippocampal atrophy compared to conventional PCI via Neuro-Oncology Advance Access Abstract Background Reducing radiation dose to the hippocampus with hippocampal avoidance prophylactic cranial irradiation (HA-PCI) is proposed to prevent cognitive decline. It has, however, not been investigated whether hippocampal atrophy is actually mitigated by this approach. Here, we determined whether HA-PCI reduces hippocampal atrophy. Additionally we evaluated neurotoxicity of (HA-)PCI to other brain regions. Finally, we evaluated associations of hippocampal atrophy and brain neurotoxicity with memory decline. Methods High quality research MRI scans were acquired in the multicenter, randomized phase 3 trial NCT01780675. Hippocampal atrophy was evaluated 4 months (57 HAPCI patients and 46 PCI patients) and 12 months (28 HAPCI patients and 27 PCI patients) after (HA-)PCI. We additionally studied multimodal indices of brain injury. Memory was assessed with the Hopkins Verbal Learning Test Revised (HVLT-R). Results HA-PCI r educed hippocampal atrophy at 4 months (1.8% for HA-PCI and 3.0% for PCI) and at 12 months (3.0% for HA-PCI and 5.8% for PCI). Both HA-PCI and PCI were associated with considerable reductions of gray matter and normal appearing white matter, increases of white matter hyperintensities and brain aging. There were no significant associations between hippocampal atrophy and memory. Conclusions HA-PCI reduces hippocampal atrophy at 4 and 12 months compared to regular PCI. Both types of radiotherapy are associated with considerable brain injury. We did not find evidence for excessive brain injury after HA-PCI relative to PCI. Hippocampal atrophy was not associated with memory decline in this population as measured with HVLT-R. The usefulness of HA-PCI is still subject to debate. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor

alexandrossfakianakis shared this article with you from Inoreader Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor via Neuro-Oncology Advance Access Abstract Background Recurrent atypical teratoid/rhabdoid tumor (AT/RT) is, most often, a fatal pediatric malignancy with limited curative options. Methods We conducted a phase II study of Aurora kinase A inhibitor alisertib in patients aged <22 years with recurrent AT/RT. Patients received alisertib once daily (80 mg/m 2 as enteric-coated tablets or 60 mg/m 2 as liquid formulation) on Days 1–7 of a 21-day cycle until progressive disease (PD) occurred. Alisertib plasma concentrations were measured in cycle 1 on Days 1 (single dose) and 7 (steady state) and analyzed with noncompartmental pharmacokinetics. Trial efficacy end point was ≥10 participants with stable disease (SD) or better at 12 weeks. Results SD (n=8) and partial response (PR) (n=1) were observed among 30 evaluable patients. Progression-free survival (PFS) was 30.0% ± 7.9% at 6 months and 13.3% ± 5.6% at 1 year. One-year overa ll survival (OS) was 36.7% ± 8.4%. Two patients continued treatment for >12 months. PFS did not differ by AT/RT molecular groups. Neutropenia was the most common adverse effect (n=23/30, 77%). The 22 patients who received liquid formulation had a higher mean maximum concentration (Cmax) of 10.1 ± 3.0 µM and faster time to Cmax (Tmax = 1.2 ± 0.7 h) than those who received tablets (Cmax = 5.7 ± 2.4 µM, Tmax = 3.4 ± 1.4 h). Conclusions Although the study did not meet pre-determined efficacy end point, single agent alisertib was well tolerated by children with recurrent AT/RT, and SD or PR was observed in approximately a third of the patients. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Overexpression of TIGAR and HO-1 in peripheral blood mononuclear cells (PBMCs) of breast cancer patients treated with radiotherapy

alexandrossfakianakis shared this article with you from Inoreader Overexpression of TIGAR and HO-1 in peripheral blood mononuclear cells (PBMCs) of breast cancer patients treated with radiotherapy via International Journal of Radiation Biology: Table of Contents: Taylor and Francis . View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Dedicated isotropic 3-D T1 SPACE sequence imaging for radiosurgery planning improves brain metastases detection and reduces the risk of intracranial relapse

alexandrossfakianakis shared this article with you from Inoreader Dedicated isotropic 3-D T1 SPACE sequence imaging for radiosurgery planning improves brain metastases detection and reduces the risk of intracranial relapse via radiotheraphy Publication date: Available online 2 June 2022 Source: Radiotherapy and Oncology Author(s): Tugce Kutuk, Kevin J. Abrams, Martin C. Tom, Muni Rubens, Haley Appel, Charif Sidani, Matthew D. Hall, Ranjini Tolakanahalli, D. Jay J. Wieczorek, Alonso N. Gutierrez, Michael W. McDermott, Manmeet S. Ahluwalia, Minesh P. Mehta, Rupesh Kotecha View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Depolarization of echo chambers by random dynamical nudge

alexandrossfakianakis shared this article with you from Inoreader Depolarization of echo chambers by random dynamical nudge via Earth and environmental sciences : nature.com subject feeds View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

First case of human Brucella canis infection in the Netherlands

alexandrossfakianakis shared this article with you from Inoreader First case of human Brucella canis infection in the Netherlands via Clinical Infectious Diseases Advance Access Abstract A patient was diagnosed with B. canis following exposure to infected dogs in her breeding facility. Transboundary spread of B. canis trough (illegal) import of infected dogs to non-endemic countries in Europe suggest that B. canis infection should be considered in European patients with occupational exposure to dogs. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients

alexandrossfakianakis shared this article with you from Inoreader Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients via Clinical Infectious Diseases Advance Access Abstract Background Paxlovid was granted emergency use authorization for the treatment of mild to moderate COVID-19, based on the interim analysis of EPIC-HR trial. Paxlovid effectiveness needs to be assessed in a noncontrolled setting. In this study we used population-based real world data to evaluate the effectiveness of Paxlovid. Methods The database of the largest healthcare provider in Israel was used to identify all adults aged 18 years or older with first ever positive test for SARS-CoV-2 between January and February 2022, who were at high risk for severe COVID-19 and had no contraindications for Paxlovid use. Patients were included irrespective of their COVID-19 vaccination status. Cox hazard regression was used to estimate the 28 day HR for severe COVID-19 or mortality with Paxlovid examined as time-dependent variable. Results Overall, 180,351 eligible were included, of them only 4,737 (2.6%) were treated with Paxlovid , and 135,482 (75.1%) had adequate COVID-19 vaccination status. Both Paxlovid and adequate COVID-19 vaccination status were associated with significant decrease in the rate of severe COVID-19 or mortality with adjusted HR 0.54 (95% CI, 0.39-0.75) and 0.20 (95% CI, 0.17-0.22), respectively. Paxlovid appears to be more effective in older patients, immunosuppressed patients, and patients with underlying neurological or cardiovascular disease (interaction p-value <0.05 for all). No significant interaction was detected between Paxlovid treatment and COVID-19 vaccination status. Conclusions This study suggests that in the era of omicron and in real life setting Paxlovid is highly effective in reducing the risk of severe COVID-19 or mortality. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

<> NEW! Social SEO <>

Hi,

Get some SEO action with the latest Social SEO Strategy, our Social Signals
Boost, which will improve your ranks in just 1 week, safely and permanently

check more details about our plans here
https://realsocialsignals.co/buy-social-signals/









Unsubscribe:
https://mgdots.co/unsubscribe/

Novel technique to prevent or correct open‐mouth deformity after bilateral mandibular resection: Use of tensor fascia lata slings

alexandrossfakianakis shared this article with you from Inoreader Novel technique to prevent or correct open‐mouth deformity after bilateral mandibular resection: Use of tensor fascia lata slings via Head & Neck Abstract Open-mouth deformity after mandibular resection presents a challenge for surgeons and patients, contributing to significant functional and cosmetic morbidity. We present an innovative surgical technique to prevent or correct open-mouth deformity. Tensor fascia lata slings were utilized in combination with maxillomandibular fixation to surgically correct or prevent open-mouth deformity in four patients who had previously undergone mandibulectomy or at the time of a contralateral mandibulectomy following prior hemimandibulectomy and reconstruction. Two patients achieved favorable outcomes, including oral competence and improved resting jaw position, while open-mouth deformity could not be corrected for one patient. Another patient remains in the early postoperative period following a secondary procedure to correct open-mouth deformity. Open-mouth deformity is a functional/aesthetic problem that has not been addressed in the literature. Use of tensor fascia lata slings to suspend the mandible is a novel approach to the surgical management of open-mouth deformity. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Prevention of Neisseria gonorrhoeae with meningococcal B vaccine: a matched cohort study in Southern California

alexandrossfakianakis shared this article with you from Inoreader Prevention of Neisseria gonorrhoeae with meningococcal B vaccine: a matched cohort study in Southern California via Clinical Infectious Diseases Advance Access Abstract Background Neisseria gonorrhoeae is acquiring increasing resistance to available oral antibiotics, and current screening and treatment approaches have not decreased gonorrhea incidence. Although a gonorrhea-specific vaccine does not exist, N. gonorrhoeae shares much of its genome with Neisseria meningitidis, notably critical antigenic determina nts including outer membrane vesicles (OMV). Prior observational studies have suggested that OMV-based meningococcal serogroup B vaccines confer protection against gonorrhea. Methods We conducted a matched cohort study from 2016-2020 to examine the association of OMV-containing recombinant meningococcal serogroup B vaccine (4CMenB) with gonorrhea infection among teens and young adults at Kaiser Permanente Southern California. Recipients of 4CMenB were matched in a ratio of 1:4 to recipients of non-OMV-containing polysaccharide-conjugate vaccine targeting serotypes A, C, W, Y ("MenACWY") who had not received 4CMenB and were followed for incident gonorrhea. We used Cox proportional hazards regression to compare gonorrhea rates among recipients of 4CMenB vs MenACWY, adjusting for potential confounders. We conducted the same analysis with chlamydia as a negative control outcome. Results The study included 6,641 recipients of 4CMenB matched to 26,471 recipients of M enACWY. During follow-up, gonorrhea incidence rates per 1000 person-years (95% CI) were 2.0 (1.3-2.8) for recipients of 4CMenB and 5.2 (4.6-5.8) for recipients of MenACWY. In adjusted analyses, gonorrhea rates were 46% lower among recipients of 4CMenB vs MenACWY (HR [95% CI] 0.54 [0.34-0.86]), but chlamydia rates were similar between vaccine groups (HR [95% CI] 0.98 [0.82-1.17]). Conclusions These results suggest cross-protection of 4CMenB against gonorrhea, supporting the potential for vaccination strategies to prevent gonorrhea. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.